Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
miércoles, 15 de mayo de 2024
THE OBESITY REVOLUTION A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. Known as GLP-1-based drugs, this medication class could have the medical and societal impact of blockbuste…
https://www.statnews.com/category/the-obesity-revolution/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9UQ02Vdmn6qc85sOD1OAP7ngwMw3YxDr-pqnDv5P32wSoyWovTdZotFxdAzNc0-cpk1LWexoEbYy6iDWnBs8ycJWJfFg&_hsmi=307106714&utm_content=307106714&utm_source=hs_email
Since GLP-1 drugs began revolutionizing the way we consider addressing obesity last year, academics have wondered if the injectable treatments could affect people’s cravings for substances. But drug companies have yet to get involved — until now. Novo Nordisk, which makes Ozempic and Wegovy, will test whether GLP-1 drugs can help people with alcohol-associated liver disease.
The company will not test the drugs purely in relation to substance misuse. The primary outcome tested in the nine-month study will be changes in liver scarring, and one of the secondary outcomes is changes in alcohol consumption. The trial comes at a time when alcohol-associated liver disease has been surging among younger people and women, making it the leading cause for transplant in the U.S. Read more from my colleagues Isa Cueto and Elaine Chen.
The new weight loss drugs are revolutionizing our understanding of desire. Food cravings could be just the beginning
Megan Molteni
By Megan Molteni
https://www.statnews.com/2023/07/10/new-weight-loss-drugs-wegovy-food-cravings/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-8j03E9NQeNhYihTgykm91sB-gNAb1e4iUKlhNBCT-D1I-vjiSCl-88o1hR3PgvF3Jn_2TJMp61w2B4ys4RHU2CT_roRg&_hsmi=307106714&utm_content=307106714&utm_source=hs_email
Novo to test Wegovy and other obesity drugs against alcohol-related liver disease
Isabella Cueto
Elaine Chen
By Isabella Cueto and Elaine Chen May 14, 2024
https://www.statnews.com/2024/05/14/wegovy-alcohol-related-liver-disease-novo-nordisk/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9gpD_qgUAhkXtpSE_NY4PB0PLfWqFK2O7Nh6uHZMRcbdmdXrv59oBOb4MsIPzDU9jfK8hawhxd1SMLDHZ1CBVf9m-Z6A&_hsmi=307106714&utm_content=307106714&utm_source=hs_email
No hay comentarios:
Publicar un comentario